ATE330637T1 - Immunoliposomen zur optimierung der internalisierung in zielzellen - Google Patents

Immunoliposomen zur optimierung der internalisierung in zielzellen

Info

Publication number
ATE330637T1
ATE330637T1 AT97917769T AT97917769T ATE330637T1 AT E330637 T1 ATE330637 T1 AT E330637T1 AT 97917769 T AT97917769 T AT 97917769T AT 97917769 T AT97917769 T AT 97917769T AT E330637 T1 ATE330637 T1 AT E330637T1
Authority
AT
Austria
Prior art keywords
immunoliposomes
target cells
growth
inhibiting
internalization
Prior art date
Application number
AT97917769T
Other languages
German (de)
English (en)
Inventor
Christopher C Benz
Demetrois Papahadjopoulos
John W Park
Keelung Hong
Dmitri Kirpotin
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE330637T1 publication Critical patent/ATE330637T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT97917769T 1996-04-18 1997-04-01 Immunoliposomen zur optimierung der internalisierung in zielzellen ATE330637T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/634,197 US6214388B1 (en) 1994-11-09 1996-04-18 Immunoliposomes that optimize internalization into target cells

Publications (1)

Publication Number Publication Date
ATE330637T1 true ATE330637T1 (de) 2006-07-15

Family

ID=24542800

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917769T ATE330637T1 (de) 1996-04-18 1997-04-01 Immunoliposomen zur optimierung der internalisierung in zielzellen

Country Status (9)

Country Link
US (4) US6214388B1 (enExample)
EP (2) EP1655039A3 (enExample)
JP (1) JP2000510825A (enExample)
AT (1) ATE330637T1 (enExample)
AU (1) AU2601297A (enExample)
CA (1) CA2249352C (enExample)
DE (1) DE69736178T2 (enExample)
ES (1) ES2263175T3 (enExample)
WO (1) WO1997038731A1 (enExample)

Families Citing this family (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
KR19990029749A (ko) * 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
ATE271376T1 (de) * 1998-02-23 2004-08-15 Cilag Ag Int Liposomale erythropoietin-dispersion
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
AU1678900A (en) * 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
JP2002526422A (ja) * 1998-10-02 2002-08-20 ウィンディー ヒル テクノロジー インコーポレイテッド 乳癌の同定、診断、及び治療の方法
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
WO2000054807A1 (en) * 1999-03-17 2000-09-21 Mitsubishi Chemical Corporation Ligand-bonded complex
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
EP1645289A1 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU2136501A (en) * 1999-12-10 2001-06-18 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
CN109395082A (zh) 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
EP2052742A1 (en) 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
HUP0101480A2 (hu) * 2001-04-11 2004-01-28 István Horváth Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228305A1 (en) 2002-01-02 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003215254A1 (en) 2002-02-13 2003-09-04 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
KR100470535B1 (ko) * 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
DK2263691T3 (da) 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
DK2364996T3 (en) 2002-09-27 2017-02-06 Xencor Inc Optimized Fc variants and methods for their formation
AU2003300280A1 (en) * 2002-12-19 2004-07-14 Alza Corporation Method of treating angiogenic tissue growth
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
HRP20090325T1 (en) 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005037858A2 (en) * 2003-10-16 2005-04-28 University Of Massachusetts Template-directed assembly of receptor signaling complexes
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
ES2472690T3 (es) 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CA2566007C (en) 2004-05-03 2013-09-24 Hermes Biosciences, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
CN101023182B (zh) 2004-07-26 2013-04-17 健泰科生物技术公司 调节肝细胞生长因子活化的方法和组合物
AU2005295072A1 (en) * 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
JP4652414B2 (ja) 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090148385A1 (en) * 2004-11-19 2009-06-11 Koninklijke Philips Electronics, N.V. Ultrasound Contrast Agents For Molecular Imaging
BRPI0518104B8 (pt) 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
KR20070100968A (ko) * 2005-02-09 2007-10-15 제넨테크, 인크. 매트릭스 메탈로프로테아제 길항제를 사용한, ｈｅｒ2박리의 억제
CN101163503B (zh) 2005-02-23 2013-05-08 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
JP2008536944A (ja) * 2005-04-22 2008-09-11 アルザ・コーポレーシヨン Ｈｅｒ２細胞受容体を標的とするためのイムノリポソーム組成物
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
US8998881B2 (en) * 2005-08-10 2015-04-07 Alza Corporation Method for delivering drugs to tissue under microjet propulsion
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ES2272178B1 (es) * 2005-09-19 2008-03-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
WO2007041397A2 (en) * 2005-09-30 2007-04-12 California Pacific Medical Center Targeted pharmaceuticals and ligands
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1962904A2 (en) * 2005-12-22 2008-09-03 Ivan M. Roitt Composition comprising an antigen-recognizing molecule and a lipid-based carrier
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20070281034A1 (en) * 2006-05-15 2007-12-06 Kirpotin Dmitri B Magnetic microparticles comprising organic substances
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
US8541190B2 (en) * 2006-06-28 2013-09-24 Robert M. Weis Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
US9683026B2 (en) 2006-07-19 2017-06-20 The Trustees Of The University Of Pennslyvania WSX-1/P28 as a target for anti-inflammatory responses
WO2008013918A2 (en) 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
DK2059536T3 (da) 2006-08-14 2014-04-14 Xencor Inc Optimerede antistoffer, der er rettet mod cd19
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
TWI352199B (en) * 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
WO2008116347A1 (en) 2007-03-26 2008-10-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
JPWO2009020093A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
KR101521668B1 (ko) 2007-08-30 2015-05-28 다이이찌 산쿄 가부시키가이샤 항ｅｐｈａ２ 항체
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US7982012B2 (en) 2008-03-10 2011-07-19 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
CN102124344B (zh) 2008-05-16 2015-04-01 霍夫曼-拉罗奇有限公司 生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8883211B2 (en) 2008-07-10 2014-11-11 Serina Therapeutics, Inc. Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20120027843A1 (en) * 2009-02-04 2012-02-02 Tetsuo Minamino Hb-egf bound protein complex
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
JP5624114B2 (ja) 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
WO2010114859A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP3205723A1 (en) 2009-06-26 2017-08-16 i2 Pharmaceuticals, Inc. Expression of surrogate light chains
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
SG10201408599QA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
EP2516468B1 (en) 2009-12-23 2016-03-02 Synimmune GmbH Anti-flt3 antibodies and methods of using the same
US9017669B2 (en) 2009-12-28 2015-04-28 Oncotherapy Science, Inc. Anti-CDH3 antibodies and uses thereof
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
BR112012020373A8 (pt) 2010-02-23 2018-01-02 Genentech Inc anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2011120134A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP3556396B1 (en) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
AU2011296085A1 (en) 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
TW201307385A (zh) 2010-10-25 2013-02-16 Genentech Inc 胃腸炎症和銀屑病以及哮喘的治療
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
KR20140041396A (ko) 2010-12-06 2014-04-04 메리맥 파마슈티컬즈, 인크. 안트라사이클린 화학요법제를 포함하는 erbb2-표적 면역리포좀으로의 치료에서 심장독성을 예방하기 위한 용량 및 투여
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
TW201245223A (en) 2011-02-14 2012-11-16 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
CA2827118A1 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012125614A1 (en) 2011-03-15 2012-09-20 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN109734807A (zh) 2011-03-31 2019-05-10 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
EA201490879A1 (ru) 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
AU2012352454A1 (en) 2011-12-15 2014-07-17 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN106727329B (zh) 2012-02-17 2020-11-03 效思因公司 热敏纳米颗粒制剂及其制备方法
MX353382B (es) 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
PT2825157T (pt) 2012-03-16 2018-12-14 Merck Patent Gmbh Lípidos de aminoácidos
AU2013231638B2 (en) 2012-03-16 2017-10-12 Merck Patent Gmbh Targeting aminoacid lipids
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
RU2682451C2 (ru) 2012-04-27 2019-03-19 Дайичи Санкио Компани, Лимитед Антитела к robo4
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
SG10201701165TA (en) 2012-08-14 2017-03-30 Univ Nanyang Tech Angiopoietin-like 4 antibody and a method of its use in cancer treatment
RU2015112024A (ru) 2012-10-05 2016-11-27 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
TR201908531T4 (tr) 2012-11-20 2019-08-21 Arbutus Biopharma Corp Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
AU2013355337B2 (en) * 2012-12-03 2018-07-12 Merrimack Pharmaceuticals, Inc. Combination therapy for treating HER2-positive cancers
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US11156608B2 (en) 2013-03-15 2021-10-26 The Trustees Of The University Of Pennsylvania Method for the site-specific covalent cross-linking of antibodies to surfaces
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
DK2970449T3 (da) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Enkeltkædede bindingsmolekyler, der omfatter n-terminal abp
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
US9884126B2 (en) 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
HUE050451T2 (hu) 2013-05-31 2020-12-28 Genentech Inc Anti-fal-teichonsav antitestek és konjugátumok
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
JP6509735B2 (ja) 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
MX377344B (es) 2014-07-31 2025-03-07 Amgen Res Munich Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016022723A1 (en) 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
JP6751393B2 (ja) 2014-12-03 2020-09-02 ジェネンテック， インコーポレイテッド 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
JP6742314B2 (ja) 2014-12-03 2020-08-19 ジェネンテック， インコーポレイテッド 抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
HUE049791T2 (hu) 2015-02-19 2020-10-28 Compugen Ltd PVRIG elleni antitestek és alkalmazási eljárások
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
DK3283524T3 (da) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
WO2016183387A1 (en) 2015-05-12 2016-11-17 The Trustees Of The University Of Pennsylvania Compositions and methods for making antibody conjugates
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
HK1255200A1 (zh) 2015-05-29 2019-08-09 F. Hoffmann-La Roche Ag 癌症中pd-l1启动子甲基化
CA2991980A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
TW202243677A (zh) 2015-08-21 2022-11-16 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
ES3007182T3 (en) 2015-10-06 2025-03-19 Hoffmann La Roche Method for treating multiple sclerosis
CN108366965B (zh) 2015-10-16 2021-10-01 易普森生物制药有限公司 稳定喜树碱药物组合物
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CN114716557A (zh) 2016-02-03 2022-07-08 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3468997B1 (en) 2016-06-08 2023-09-13 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
CA3036829A1 (en) 2016-09-14 2018-03-22 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
AU2017354903B2 (en) 2016-11-02 2023-04-13 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
LT3561057T (lt) 2016-12-22 2025-09-25 Daiichi Sankyo Company, Limited Anti-cd3 antikūnas ir molekulė, kurios sudėtyje yra minėtas antikūnas
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
AU2018218753A1 (en) 2017-02-07 2019-09-26 Daiichi Sankyo Company, Limited Anti-GPRC5D antibody and molecule containing same
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
TWI868050B (zh) 2017-05-05 2025-01-01 美商安進公司 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
AU2018277838C1 (en) 2017-05-31 2025-08-07 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
EP3693012A4 (en) 2017-10-05 2021-07-21 Daiichi Sankyo Company, Limited CYTOTOXIC T-CELL DEPLOYMENT COMPOSITION
WO2019118426A1 (en) 2017-12-11 2019-06-20 Amgen Inc. Continuous manufacturing process for bispecific antibody products
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
WO2019197607A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
AU2019269588A1 (en) * 2018-05-15 2020-12-10 Flagship Pioneering Innovations Vi, Llc Pathogen control compositions and uses thereof
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
EP4272731A3 (en) 2018-12-11 2024-02-14 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CA3137494A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
IL296601A (en) 2020-03-19 2022-11-01 Amgen Inc Antibodies against mucin 17 and their uses
CA3194386A1 (en) 2020-10-06 2022-04-14 Ying Ding Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
JP2023549116A (ja) 2020-11-06 2023-11-22 アムジエン・インコーポレーテツド 選択性が増大した多標的二重特異性抗原結合分子
WO2022210485A1 (ja) 2021-03-29 2022-10-06 第一三共株式会社 安定な多重特異性分子及びその利用
JP2024518369A (ja) 2021-05-06 2024-05-01 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング 増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20220372114A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
EP4410277A4 (en) * 2021-09-30 2025-10-22 Nof Corp LIPID NANOPARTICLES WITH CELLULAR DIRECTIONALITY
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
EP4587474A2 (en) 2022-09-14 2025-07-23 Amgen Inc. Bispecific molecule stabilizing composition
UY40797A (es) 2023-06-14 2024-12-31 Amgen Inc Moléculas captadoras de enmascaramiento de células t
WO2026005603A1 (en) 2024-06-25 2026-01-02 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) A method for preparing liposomes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ES2085920T3 (es) * 1989-06-23 1996-06-16 Liposome Co Inc Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4155696A (en) * 1994-11-09 1996-06-06 Regents Of The University Of California, The Immunoliposomes that optimize internalization into target cells
JP3502885B2 (ja) 2000-01-12 2004-03-02 村田機械株式会社 画像拡大・縮小方法及びそれに用いるクロック生成回路

Also Published As

Publication number Publication date
AU2601297A (en) 1997-11-07
US20070031484A1 (en) 2007-02-08
EP1655039A3 (en) 2010-01-27
EP1655039A2 (en) 2006-05-10
US6214388B1 (en) 2001-04-10
CA2249352A1 (en) 1997-10-23
US7871620B2 (en) 2011-01-18
WO1997038731A1 (en) 1997-10-23
US7135177B2 (en) 2006-11-14
US20010016196A1 (en) 2001-08-23
EP0912198A4 (en) 2000-04-12
CA2249352C (en) 2012-06-05
EP0912198A1 (en) 1999-05-06
DE69736178T2 (de) 2007-05-24
US20100068255A1 (en) 2010-03-18
EP0912198B1 (en) 2006-06-21
US7507407B2 (en) 2009-03-24
ES2263175T3 (es) 2006-12-01
DE69736178D1 (de) 2006-08-03
JP2000510825A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
ATE330637T1 (de) Immunoliposomen zur optimierung der internalisierung in zielzellen
DK0833620T3 (da) FGFR3, en markør for mesenkymale progenitorceller
NO993258L (no) Peptid-lipidkonjugater, liposomer og liposomal legemiddelavlevering
CA2264901A1 (fr) Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE423547T1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
CO4830493A1 (es) Anticuerpos contra cd40 humano
WO1997014806A3 (en) Delivery of biologically active polypeptides
BR0012429A (pt) Fórmulações para il-11
TR199801541A2 (xx) N,N-Dietil-m-Toluamid'in (DEET) Anti-Parazit i�levi
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69813249D1 (de) Düse zur abgabe eines aktiven materiales
AU4751797A (en) Defined systems for epithelial cell culture and use thereof
EP1364657A4 (en) AGAINST TUMORS IN HEMATOPOETIC ORGANS
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
DK0801571T3 (da) Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
WO2001090159A3 (en) Compositions and methods for delivery of a molecule into a cell

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties